Market Overview:
The global endocrine therapy drugs for breast cancer market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of breast cancer, rising awareness about early diagnosis and treatment options, and technological advancements in the field of endocrine therapy drugs for breast cancer. Based on type, tamoxifen is expected to account for the largest share of the global endocrine therapy drugs for breast cancer market in 2018. This can be attributed to its high efficacy and long track record in treating estrogen receptor-positive (ER+) tumors. Tamoxifen is also relatively affordable as compared to other types of endocrine therapy drugs available in the market. Based on application, hospitals are expected to account for the largest share of the global endocrine therapy drugs for breast cancer market in 2018.
Product Definition:
Endocrine therapy drugs for breast cancer are used to block the hormones that can fuel tumor growth. They are important because they can shrink tumors, slow their growth, or stop them from spreading.
Tamoxifen:
Tamoxifen is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer. It was first approved by the U.S. FDA for breast cancer in 1997 and later for other uses including gynecological, prostate, and lung cancers; it has also been used as an anti-aromatase agent to treat women with advanced ovarian cancer.
Anastrozole:
Anastrozole (AIZO) is an aromatase inhibitor that was first synthesized by Burroughs Wellcome in England. It was later developed into a drug by AstraZeneca and marketed as Arastrozole under the brand name of Eribulin in Europe and Japan. Anastrozole is currently marketed as Aizobel in more than 50 countries worldwide, including the U.S.
Application Insights:
Based on the application, the global endocrine therapy drugs for breast cancer market is segmented into hospital, clinic and other. The hospital segment dominated the overall market in terms of revenue in 2017 owing to high usage rates of aromatase inhibitors such as anastrozole and letrozole across various hospitals globally. Moreover, increasing research activities pertaining to endocrine-based therapies for advanced breast cancer are further expected to drive demand over the forecast period.
The clinic application segment is anticipated to witness a lucrative CAGR during the forecast period due to rising awareness about early diagnosis and effective treatment options among women aged 40 years or above who have been diagnosed with hormone-receptor-positive tumors (estrogen/progesterone receptor positive). Increasing cases of postmenopausal women suffering from hormone-receptor positive breast carcinoma drives demand for these drugs at clinics worldwide.
Regional Analysis:
North America dominated the global endocrine therapy drugs for breast cancer market and accounted for the largest revenue share of over 45.0% in 2017. This growth can be attributed to various factors such as high healthcare expenditure, rising awareness about available treatment options, presence of key manufacturers in this region, and increasing R&D activities by major players to develop novel therapies. Moreover, an increase in incidence rates of breast cancer has led to a rise in demand for these drugs during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to improving economic conditions and growing consumer disposable income levels that enable them access better quality healthcare services along with increased spending on pharmaceutical products & solutions. Furthermore, government initiatives encouraging women participation are also anticipated boost regional market growth during the estimated time frame (2018-2030).
Growth Factors:
- Increasing incidence of breast cancer
- Growing awareness about the benefits of endocrine therapy drugs for breast cancer treatment
- Rising demand for better and more effective therapies
- Technological advancements in the field of endocrine therapy drugs for breast cancer treatment
- Availability of government funding and support for research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Endocrine Therapy Drugs for Breast Cancer Market Research Report
By Type
Tamoxifen, Anastrozole, Exemestane, Letrozole, Goserelin, Fulvestrant
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Teva, Amneal Pharms, AstraZeneca, Novartis, Intas Pharmaceuticals, Chemo, Accure Labs, Natco, Zydus Pharmaceuticals, Sanofi, Pfizer, Mylan , Wockhardt, Cipla, Actiza Pharmaceutical, Hikma Pharmaceuticals, Shanghai Forward Technology, Bayer, Liaoning Kangtai Pharmaceutical, Fu 'an Pharmaceutical Group, Apotex, Taro, Sun Phamaceutical, Intas Pharmaceuticals, Chemo, Accure Labs, Sun Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Endocrine Therapy Drugs for Breast Cancer Market Report Segments:
The global Endocrine Therapy Drugs for Breast Cancer market is segmented on the basis of:
Types
Tamoxifen, Anastrozole, Exemestane, Letrozole, Goserelin, Fulvestrant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Amneal Pharms
- AstraZeneca
- Novartis
- Intas Pharmaceuticals
- Chemo
- Accure Labs
- Natco
- Zydus Pharmaceuticals
- Sanofi
- Pfizer
- Mylan
- Wockhardt
- Cipla
- Actiza Pharmaceutical
- Hikma Pharmaceuticals
- Shanghai Forward Technology
- Bayer
- Liaoning Kangtai Pharmaceutical
- Fu 'an Pharmaceutical Group
- Apotex
- Taro
- Sun Phamaceutical
- Intas Pharmaceuticals
- Chemo
- Accure Labs
- Sun Pharmaceutical
Highlights of The Endocrine Therapy Drugs for Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tamoxifen
- Anastrozole
- Exemestane
- Letrozole
- Goserelin
- Fulvestrant
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endocrine Therapy Drugs for Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endocrine therapy drugs are medications that are used to treat breast cancer. These drugs work by affecting the hormones that are responsible for regulating many aspects of a person's health, including their growth and development, their moods and emotions, and their reproductive functions.
Some of the major players in the endocrine therapy drugs for breast cancer market are Teva, Amneal Pharms, AstraZeneca, Novartis, Intas Pharmaceuticals, Chemo, Accure Labs, Natco, Zydus Pharmaceuticals, Sanofi, Pfizer, Mylan , Wockhardt, Cipla, Actiza Pharmaceutical, Hikma Pharmaceuticals, Shanghai Forward Technology, Bayer, Liaoning Kangtai Pharmaceutical, Fu 'an Pharmaceutical Group, Apotex, Taro, Sun Phamaceutical, Intas Pharmaceuticals, Chemo, Accure Labs, Sun Pharmaceutical.
The endocrine therapy drugs for breast cancer market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Endocrine Therapy Drugs for Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Endocrine Therapy Drugs for Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Endocrine Therapy Drugs for Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Endocrine Therapy Drugs for Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Endocrine Therapy Drugs for Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 Endocrine Therapy Drugs for Breast Cancer Market Size and Y-o-Y Growth
4.5.2 Endocrine Therapy Drugs for Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global Endocrine Therapy Drugs for Breast Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
5.2.1 Tamoxifen
5.2.2 Anastrozole
5.2.3 Exemestane
5.2.4 Letrozole
5.2.5 Goserelin
5.2.6 Fulvestrant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Endocrine Therapy Drugs for Breast Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Endocrine Therapy Drugs for Breast Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Endocrine Therapy Drugs for Breast Cancer Analysis and Forecast
9.1 Introduction
9.2 North America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
9.6.1 Tamoxifen
9.6.2 Anastrozole
9.6.3 Exemestane
9.6.4 Letrozole
9.6.5 Goserelin
9.6.6 Fulvestrant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Endocrine Therapy Drugs for Breast Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
10.6.1 Tamoxifen
10.6.2 Anastrozole
10.6.3 Exemestane
10.6.4 Letrozole
10.6.5 Goserelin
10.6.6 Fulvestrant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Endocrine Therapy Drugs for Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
11.6.1 Tamoxifen
11.6.2 Anastrozole
11.6.3 Exemestane
11.6.4 Letrozole
11.6.5 Goserelin
11.6.6 Fulvestrant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Endocrine Therapy Drugs for Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
12.6.1 Tamoxifen
12.6.2 Anastrozole
12.6.3 Exemestane
12.6.4 Letrozole
12.6.5 Goserelin
12.6.6 Fulvestrant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Endocrine Therapy Drugs for Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Type
13.6.1 Tamoxifen
13.6.2 Anastrozole
13.6.3 Exemestane
13.6.4 Letrozole
13.6.5 Goserelin
13.6.6 Fulvestrant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Endocrine Therapy Drugs for Breast Cancer Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Endocrine Therapy Drugs for Breast Cancer Market: Competitive Dashboard
14.2 Global Endocrine Therapy Drugs for Breast Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Amneal Pharms
14.3.3 AstraZeneca
14.3.4 Novartis
14.3.5 Intas Pharmaceuticals
14.3.6 Chemo
14.3.7 Accure Labs
14.3.8 Natco
14.3.9 Zydus Pharmaceuticals
14.3.10 Sanofi
14.3.11 Pfizer
14.3.12 Mylan
14.3.13 Wockhardt
14.3.14 Cipla
14.3.15 Actiza Pharmaceutical
14.3.16 Hikma Pharmaceuticals
14.3.17 Shanghai Forward Technology
14.3.18 Bayer
14.3.19 Liaoning Kangtai Pharmaceutical
14.3.20 Fu 'an Pharmaceutical Group
14.3.21 Apotex
14.3.22 Taro
14.3.23 Sun Phamaceutical
14.3.24 Intas Pharmaceuticals
14.3.25 Chemo
14.3.26 Accure Labs
14.3.27 Sun Pharmaceutical
